Clinical trialsCompany release

Eupraxia completes Phase 2b enrolment for EoE candidate EP-104GI, interim data due December

Eupraxia Pharmaceuticals Inc. (EPRX) · Tue 10 Nov 2026

The company reached its 120-patient target in the placebo-controlled RESOLVE study and reported Q3 2026 results, with cash it says lasts into the second half of 2028.

Eupraxia Pharmaceuticals said on 10 November 2026 that it has reached its target enrolment of 120 patients in the placebo-controlled Phase 2b portion of RESOLVE, its trial of EP-104GI in eosinophilic esophagitis (EoE). Interim results from this part of the study are expected in December 2026.

The company also published its third-quarter 2026 financial results. It reported a net loss of $15.2 million for the quarter, and cash plus short-term investments of about $126 million. Eupraxia says this is enough to fund operations into the second half of 2028.

Earlier open-label Phase 1b/2a data showed that 64% of patients remained in clinical remission over 52 weeks. That study had no placebo comparator, so the randomised, placebo-controlled Phase 2b data will be the first controlled test of the product in this indication.

The summary provided does not give further detail on the interim analysis, such as endpoints, timing within December or the dosing regimens tested.

What it means for your team

  • Interim placebo-controlled efficacy and safety data for EP-104GI are expected in December 2026, a near-term milestone for those tracking EoE pipelines.
  • The 64% remission figure over 52 weeks comes from an open-label study, so it should be read cautiously until controlled data are available.
  • Eupraxia's stated cash runway into the second half of 2028 suggests the company is funded through the next stage of development, though the source gives no regulatory timetable.

Company's press release (SEC filing): Eupraxia Pharmaceuticals Inc. ↗

Article written by VigiEye from the official source (Eupraxia Pharmaceuticals Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →